Ovid Therapeutics
OVID
60 hedge funds and large institutions have $71.7M invested in Ovid Therapeutics in 2022 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 11 increasing their positions, 22 reducing their positions, and 8 closing their positions.
13% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 8
9% more capital invested
Capital invested by funds: $65.5M → $71.7M (+$6.19M)
4.17% more ownership
Funds ownership: 50.54% → 54.72% (+4.2%)
2% more funds holding
Funds holding: 59 → 60 (+1)
50% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 22
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$3.94M |
| 2 |
MAP
Madison Avenue Partners
New York
|
+$2.26M |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$283K |
| 4 |
E
Ergoteles
New York
|
+$129K |
| 5 |
Jane Street
New York
|
+$76.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$2.83M |
| 2 |
BlackRock
New York
|
-$741K |
| 3 |
D.E. Shaw & Co
New York
|
-$315K |
| 4 |
Bank of New York Mellon
New York
|
-$239K |
| 5 |
DA
DCF Advisers
Greenwich,
Connecticut
|
-$157K |
OVID Hedge Fund Activity: Q4 2022 in Review
60 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in Ovid Therapeutics (OVID) for Q4 2022, worth a combined $71.7M — up 9.5% from $65.5M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new OVID positions and 8 closed out — a net gain of 1 holder — while 11 added to existing stakes and 22 trimmed.
The largest buyer was Rubric Capital Management (New York), adding an estimated $3.94M. The largest seller was Stonepine Capital Management, exiting entirely with an estimated $2.83M sold.
- 60 institutional investors held Ovid Therapeutics (OVID) as of Q4 2022, up from 59 in Q3 2022.
- Funds reported $71.7M of Ovid Therapeutics stock for Q4 2022, up 9.5% quarter-over-quarter.
- 9 funds opened new Ovid Therapeutics positions in Q4 2022 and 8 closed out, a net change of +1 holder.
- The largest Ovid Therapeutics buyer in Q4 2022 was Rubric Capital Management (New York), an estimated $3.94M added.
- The largest Ovid Therapeutics seller in Q4 2022 was Stonepine Capital Management, an estimated $2.83M sold.
Based on aggregated 13F filings for Q4 2022.